Searching for Eden Semaglutide? Here's the UK Reality

You've seen semaglutide offered under different names, here's what matters

Weight-loss services sometimes trade under a brand, a clinic name, or a platform identity that bears no resemblance to the medicine's own name. That can make researching semaglutide confusing, because the same active ingredient appears under different service umbrellas. The thing that stays constant is the medicine itself: semaglutide, sold in the UK as Wegovy, is a once-weekly subcutaneous injection made by Novo Nordisk and licensed for weight management since 2023. A higher 7.2mg maintenance dose was approved by the MHRA in January 2026, and a dedicated single-dose 7.2mg pen followed in April 2026, a meaningful step forward for people who respond well and want to extend their results.

What any legitimate service must provide is a proper clinical assessment before a prescription is issued. The prescriber looks at your BMI, any relevant health conditions, your medication history and your personal circumstances. No algorithm issues a prescription on its own; a real clinician makes that call. If a service you've found doesn't make that process explicit, it is worth pausing before proceeding. You can verify any UK online pharmacy in under a minute using the GPhC pharmacy register.

Semaglutide comes in two UK-licensed forms for weight loss, the weekly injection and, more recently, a daily tablet. For a fuller picture of how they compare and which might suit your situation, the semaglutide overview covers both in detail.

What the clinical evidence shows, and what it doesn't promise

The trial data for semaglutide 2.4mg is well-established. The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults over 68 weeks and found an average body-weight reduction of around 15% at the 2.4mg maintenance dose, alongside lifestyle changes. That figure comes from a controlled trial; individual results vary, and the medicine works best alongside a reduced-calorie diet and increased physical activity, a point every prescriber will raise with you.

A question our prescribers hear most weeks is whether higher doses always mean better results. If you want to understand what moving up the titration schedule looks like in practice, our semaglutide 2 page walks through what that stage of treatment involves. But reaching that dose takes time: the titration schedule starts at 0.25mg and steps up gradually, with a minimum of roughly four weeks at each level, because slower titration reduces the likelihood of gastrointestinal side effects.

Gastrointestinal effects (nausea, loose stools, constipation, reflux) are the most commonly reported. They tend to be most noticeable in the early weeks or after a dose step, and they settle for most people within a fortnight or so. The semaglutide side effects page goes into more detail on what to expect and when to contact a clinician. Semaglutide is not recommended during pregnancy, breastfeeding, or if you are actively trying to conceive, and it is not licensed for anyone under 18.

Who the UK licence covers, and the NHS route vs private

The licensed eligibility for Wegovy covers adults with a BMI of 30 or above, or a BMI of 27 or higher alongside at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. BMI alone is never the whole picture, the prescriber assesses the full clinical context.

NHS access to semaglutide is governed by NICE Technology Appraisal 875, which recommends it only within specialist weight management services and for a maximum of two years. Waiting lists for those services are commonly long, and many people who meet the broad eligibility criteria don't meet the specific NHS threshold at this stage. For context on costs if you're considering the private route, the Wegovy cost and availability page covers what a private prescription realistically includes.

Privately, the route is more straightforward in terms of access: a consultation with a registered prescriber, clinical review, and (if suitable) a prescription dispensed through a GPhC-registered pharmacy. There is no referral required and no waiting list. If you are further along in your treatment and want to understand what the later stages look like, our semaglutide 3 page covers that in detail. You can also read more about how the Wegovy treatment works in practice, including what happens at each stage of treatment.

What to look for in a safe semaglutide provider

The MHRA has been clear about the risks of purchasing weight-loss medicines from unverified sources. Counterfeit pens have been found to contain insulin, and in 2025 around 20 million doses of illegally traded weight-loss medicines (worth approximately £45 million) were seized by enforcement teams. Sellers operating without proper clinical oversight (or offering these medicines without a prescription) represent a genuine safety risk, not just a regulatory one.

A regulated provider will always be findable on the GPhC register, will involve a real prescriber in every decision, and will dispense only through the licensed UK supply chain. At nume, every consultation is reviewed personally by a GPhC-registered Independent Prescriber the same day it is submitted, with photo-ID verification and live weight check built into the process. If you have questions about how the process works or want to understand what the clinical team looks at, the FAQs and the clinical team profile are good starting points.

If you're ready to find out whether semaglutide is clinically appropriate for you, speak to our prescribers through a free consultation, no commitment, no subscription, just a straightforward clinical conversation.